Finding new treatments for aggressive leukaemia

Lead researcher - Professor Tony Kouzarides, University of Cambridge
Role of the RNA methyltransferase DIMT1 in AML
Amount awarded: £238,752
Award start date: 01 Jan 2018
Award duration: 3 years (36 months)

The outlook for people with AML is bleak, and there are limited treatment options available. Finding innovative ways to treat AML is needed.

Professor Tony Kouzarides and his team at the University of Cambridge are exploring the role of enzymes in acute myeloid leukaemia (AML) cells. Enzymes speed up the chemical reactions in the cells and can also lead to the development of blood cancer.

The team have already picked out an enzyme called DIMT1 that helps AML cells grow. However, not much is known about this enzyme. Researchers will uncover new biological pathways that DIMT1 is involved in, which could help identify new ways to treat AML.